Dongguan Sunshine Group Corporation is a non-public shareholding enterprise with current assets of over 16 billion yuan and unaudited output value of 15 billion yuan in 2011. It owns a listed company, "Dongguan Sunshine Aluminum" (600673), and is currently establishing another listed company, "Dongguan Sunshine Pharmaceuticals," aiming to be listed in the second half of 2012. Additionally, it is assisting the Hong Kong-based Nanbei Brothers Company in setting up "Nanling Health Preservation," which is planned to be listed in Hong Kong. The company currently has four major production bases: Yidu, Hubei; Shaoguan, Guangdong; Zunyi, Guizhou; and Dongguan, Guangdong, employing more than 12,000 people. It is currently the largest producer in China of electronic optical foil, formed foil, hydrophilic foil, and large capacitors with diameters above φ16, as well as the largest producer of electrochemical products in Guangdong Province. With the successful joint ventures with Japan's Mitsui, Furukawa-Sky, and Kemkom, it is set to become one of the most advanced and potential R&D enterprises in aluminum processing technology in China. It is also one of the few non-public enterprises that integrate coal resources and mining, port and Yangtze River water transportation, and large-scale thermal power generation. It is one of the main units in China with a larger number of scientific researchers and better experimental equipment for developing refrigerants, fluorine resins, and fine fluorine chemicals. It is also one of the main units in China with a larger number of scientific researchers and better experimental equipment for developing solar energy raw materials, components, and system technologies. It is the world's largest producer of macrolides that has been certified by the US FDA and is the largest Tamiflu production base in China. It is one of the companies with the highest level of insulin-like biopharmaceuticals production and is the most capable in researching, registering overseas, and producing generic drugs in developed countries such as Europe and America. It is the first pharmaceutical company in China to independently develop, register, and obtain certification from both the US FDA and the EU. It is the strongest new drug R&D enterprise among Chinese companies, with a significant number of overseas experts, advanced equipment, and alignment with the US FDA. In the near future, it will make positive contributions to humanity's fight against major diseases such as cardiovascular disease, cancer, and hepatitis B, and will become the world's leading and China's largest pharmaceutical company with a complete pharmaceutical industry system, including active pharmaceutical ingredients, generic drugs, medical excipients, medical packaging materials, medical devices, Chinese cooperative patent drugs, biopharmaceuticals, new drug R&D, production, and sales. Entrusted by the Nanbei Brothers Company in Hong Kong, it manages the 50-year operating rights of the Nanling National Forest Park, as well as the food and cosmetics industries, health check-up and anti-aging centers, two elderly care bases, two golf courses, and three five-star hotels being built under the concept of the Nanling National Forest Park and the pharmaceutical industry. In 2009, the company underwent a share reform, setting up long-term equity, technical project equity, and operational equity, making many senior executives at the headquarters, subsidiaries, and factories shareholders of Dongguan Sunshine. A modern enterprise management system was established where those with permanent property have a lasting commitment.